Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Corporate

19 May 2017 New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award

CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for pioneering new medicines.

> Read More
10 April 2017 Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World

CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).

> Read More
29 March 2017 Patient Advocacy Organizations Continue to Develop Innovative Ways to Advocate for Patients

Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD) grants to support advocacy work of rare disease patient groups. These groups tackle complex legislative and public policy issues and ensure patients’ voices are heard on Capitol Hill and in statehouses across the U.S.

> Read More
01 March 2017 Largest Ever CIDP Clinical Study Completed

Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as PATH (Polyneuropathy And Treatment with Hizentra®).

> Read More
14 February 2017 FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s clinical efficacy supplement to its Biologics License Application (BLA) for Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], its intravenous immunoglobulin (IVIg).

> Read More
Page 1 of 2 Last

Share
LinkedIn Twitter Facebook Google+